Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/26082
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Deniz, Günnur | - |
dc.contributor.author | Zouali, Moncef | - |
dc.date.accessioned | 2022-04-26T07:07:21Z | - |
dc.date.available | 2022-04-26T07:07:21Z | - |
dc.date.issued | 2009-08 | - |
dc.identifier.citation | Deniz, G. vd. (2009). "Frontiers in clinical immunology 2008". Scandinavian Journal of Immunology, 70(2), 163-171. | en_US |
dc.identifier.issn | 0300-9475 | - |
dc.identifier.uri | https://doi.org/10.1111/j.1365-3083.2009.02284.x | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1111/j.1365-3083.2009.02284.x | - |
dc.identifier.uri | http://hdl.handle.net/11452/26082 | - |
dc.description.abstract | In recent years, investigations in immunology have led to progress in clinical medicine, including understanding transplant rejection, autoimmune diseases, immune deficiencies, inflammation, transplantation, cancer and the development of new vaccines. At a meeting recently held on the Mediterranean shore, advances in several facets of clinical immunology were the focus of discussion. Here, we highlight some of the debates that reflected advances in a variety of human immune disorders. | en_US |
dc.description.sponsorship | EuropeanFederation of Immunological Societies (EFIS | en_US |
dc.description.sponsorship | EJI, the International Union of Immunological Societies (IUIS) | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Common variable immunodeficiency | en_US |
dc.subject | Experimental sjogrens-syndrome | en_US |
dc.subject | Cd8(+) t-cells | en_US |
dc.subject | Rheumatoid-arthritis | en_US |
dc.subject | Peptide at-1002 | en_US |
dc.subject | Expression | en_US |
dc.subject | Receptor | en_US |
dc.subject | Disease | en_US |
dc.subject | Tuberculosis | en_US |
dc.subject | Replication | en_US |
dc.subject | Immunology | en_US |
dc.title | Frontiers in clinical immunology 2008 | en_US |
dc.type | Editorial Material | en_US |
dc.identifier.wos | 000268061600013 | tr_TR |
dc.identifier.scopus | 2-s2.0-67651246751 | tr_TR |
dc.relation.tubitak | TÜBİTAK | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji ve İmmünoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0003-0463-6818 | tr_TR |
dc.identifier.startpage | 163 | tr_TR |
dc.identifier.endpage | 171 | tr_TR |
dc.identifier.volume | 70 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.relation.journal | Scandinavian Journal of Immunology | en_US |
dc.contributor.buuauthor | Oral, Haluk Barbaros | - |
dc.contributor.researcherid | K-7285-2012 | tr_TR |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.identifier.pubmed | 19630924 | tr_TR |
dc.subject.wos | Immunology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q3 | en_US |
dc.contributor.scopusid | 7004498001 | tr_TR |
dc.subject.scopus | Chimerism; Dizygotic Twins; Karyotype 46,Xx | en_US |
dc.subject.emtree | Antigen | en_US |
dc.subject.emtree | Antiretrovirus agent | en_US |
dc.subject.emtree | B cell activating factor | en_US |
dc.subject.emtree | Bacterial toxin | en_US |
dc.subject.emtree | BCG vaccine | en_US |
dc.subject.emtree | Biological marker | en_US |
dc.subject.emtree | CD40 antigen | en_US |
dc.subject.emtree | CD40 ligand | en_US |
dc.subject.emtree | Cyclic AMP | en_US |
dc.subject.emtree | Cyclooxygenase 2 | en_US |
dc.subject.emtree | Cyclosporin A | en_US |
dc.subject.emtree | Fc receptor IIb | en_US |
dc.subject.emtree | Gamma interferon | en_US |
dc.subject.emtree | Granulocyte chemotactic protein 2 | en_US |
dc.subject.emtree | Immunoglobulin enhancer binding protein | en_US |
dc.subject.emtree | Immunoglobulin G3 | en_US |
dc.subject.emtree | Interleukin 10 | en_US |
dc.subject.emtree | Interleukin 18 | en_US |
dc.subject.emtree | Interleukin 6 | en_US |
dc.subject.emtree | Interleukin 8 | en_US |
dc.subject.emtree | Listeriolysin | en_US |
dc.subject.emtree | Phospholipase A2 | en_US |
dc.subject.emtree | Prostaglandin E2 | en_US |
dc.subject.emtree | Protein arginine deiminase | en_US |
dc.subject.emtree | Rho kinase | en_US |
dc.subject.emtree | Transcription factor NFAT | en_US |
dc.subject.emtree | Transforming growth factor beta1 | en_US |
dc.subject.emtree | Transmembrane activator and CAML interactor | en_US |
dc.subject.emtree | Unindexed drug | en_US |
dc.subject.emtree | Vpr protein | en_US |
dc.subject.emtree | Acquired immune deficiency syndrome | en_US |
dc.subject.emtree | Apoptosis | en_US |
dc.subject.emtree | Autoimmune disease | en_US |
dc.subject.emtree | Autoimmunity | en_US |
dc.subject.emtree | Bacillus anthracis | en_US |
dc.subject.emtree | Basophil | en_US |
dc.subject.emtree | BCG vaccination | en_US |
dc.subject.emtree | Behcet disease | en_US |
dc.subject.emtree | Bordetella pertussis | en_US |
dc.subject.emtree | Cancer immunization | en_US |
dc.subject.emtree | CD8+ T lymphocyte | en_US |
dc.subject.emtree | Clinical immunology | en_US |
dc.subject.emtree | Common variable immunodeficiency | en_US |
dc.subject.emtree | Conference paper | en_US |
dc.subject.emtree | Dendritic cell | en_US |
dc.subject.emtree | DNA polymorphism | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug induced cancer | en_US |
dc.subject.emtree | Endothelium cell | en_US |
dc.subject.emtree | Epigenetics | en_US |
dc.subject.emtree | Gene | en_US |
dc.subject.emtree | Gene expression | en_US |
dc.subject.emtree | Gene mutation | en_US |
dc.subject.emtree | Gene therapy | en_US |
dc.subject.emtree | Graft rejection | en_US |
dc.subject.emtree | Hemophagocytic lymphohistiocytosis | en_US |
dc.subject.emtree | Highly active antiretroviral therapy | en_US |
dc.subject.emtree | Histocompatibility | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human immunodeficiency virus 1 infection | en_US |
dc.subject.emtree | Immune deficiency | en_US |
dc.subject.emtree | Immune response | en_US |
dc.subject.emtree | Immunogenetics | en_US |
dc.subject.emtree | Immunopathology | en_US |
dc.subject.emtree | Lung alveolus macrophage | en_US |
dc.subject.emtree | Macrophage | en_US |
dc.subject.emtree | Monocyte | en_US |
dc.subject.emtree | Mycobacterium tuberculosis | en_US |
dc.subject.emtree | Natural killer cell | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Pathogenicity | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Prostate hypertrophy | en_US |
dc.subject.emtree | Protein phosphorylation | en_US |
dc.subject.emtree | Pseudomonas aeruginosa | en_US |
dc.subject.emtree | Rheumatoid arthritis | en_US |
dc.subject.emtree | Signal transduction | en_US |
dc.subject.emtree | Sjoegren syndrome | en_US |
dc.subject.emtree | Southern Europe | en_US |
dc.subject.emtree | Systemic lupus erythematosus | en_US |
dc.subject.emtree | Tuberculosis | en_US |
dc.subject.emtree | Tumor growth | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Oral_vd_2009.pdf | 96.96 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License